Due Process Continuity of Care Act

Increasing access to mental health and substance use treatment Mental health & substance use disorder workforce Modernizing Opioid Treatment Access Act (H.R. 1359/S.644) Federal funding for mental health and substance use programs, research and training Medicare telehealth flexibilities Extend federal flexibilities for teleprescribing of controlled substances H.R. 6663/S. 3364 Kid Providing Resources for Optimal Outcomes Against Fatalities (Kid PROOF) Act Reauthorization of Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities (SUPPORT) Act H.R. 5819/S. 1378, Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act H.R. 2400/S. 1165, Reentry Act H.R. 3074/S. 971, Due Process Continuity of Care Act

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

SUPPORT for Patients and Communities Reauthorization Act (HR 4531 / S 2433, S 3106, S 3393); HEAL Act (HR 4007 / S 2809); PAHPA Act (HR 4421 / S 2333); Reentry Act (HR 2400 / S 1165); Due Process Continuity of Care Act (HR 3074 / S 971); FY25 appropriations for Labor-HHS-Education, Military Construction & Veterans Affairs, and Commerce-Justice-Science; DEA rulemaking on telemedicine prescribing of controlled substances (RIN #1117-AB40); CMS Physician Fee Schedule CY25 Proposed Rule (RIN #0938-AV33);Continuing appropriations for FY25 (HR 9747, HR 10545)

Client expense: $230,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Support The Reentry Act (H.R.2400/S.1165). Support the Due Process Continuity of Care Act (H.R.3074/S.971). Support strengthening data collection and modernization, workforce and funding provisions in the reauthorization of the Pandemic and All-Hazards Preparedness Act. Support passage of the Preventing Maternal Deaths Reauthorization Act of 2023 (H.R. 3838/S. 2415). Oppose cuts to the Prevention and Public Health Fund included in proposed Senate primary care program reauthorization legislation. Support the Women's Health Protection Act. Support the Community Mental Wellness and Resilience Act of 2023.

Client expense: $17,592 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Vice President of the U.S., White House Office

H.R. 4531, SUPPORT for Patients and Communities Act H.R. 3074, Due Process Continuity of Care Act H.R. 2400, Reentry Act H.R. 8069/S. 4159 - Strengthening the Medical Examiner and Coroner System Act of 2024

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Public health legislation regarding County jail inmate access to Medicaid benefits (H.R. 2400, S. 1165, H.R. 3074, S. 971).

Client expense: Not reported · Firm income: $20,000

Womens Health Protection Act Mental Health Workforce Shortages Federal policies affecting access to contingency management services for substance use disorders S. 4246 Advancing Menopause Care and Mid-Life Womens Health Act General Menopause health policy H. R. 498 / S.1493, 9-8-8 Lifeline Cybersecurity Responsibility Act H.R. 501 Block, Report, And Suspend Suspicious Shipments Act H.R. 773/S. 3165, Homelessness and Behavioral Health Care Coordination Act of 2023 H.R. 1359/S. 644 Modernizing Opioid Treatment Access Act H.R. 1423 911 Community Crisis Responders Act of 2023 H.R. 1502 Comprehensive Opioid Recovery Centers Reauthorization Act of 2023 H.R. 2474 - The Strengthening Medicare for Patients and Providers Act H.R.2577/S.1137,DHS Suicide Prevention and Resiliency for Law Enforcement Act H.R. 3074/S. 971 The Due Process Continuity of Care Act HR 3305 Black Maternal Health Momnibus Act H.R. 3375 STOP Fentanyl Overdoses Act H.R. 3752 Parity Enforcement Act of 2023 H.R.4310/S.2233, Youth Poisoning Protection Act H.R. 4531 / S. 2433, SUPPORT for Patients and Communities Reauthorization Act of 2023 H.R. 4851, 9-8-8 Implementation Act of 2023 H.R. 4884 /S. 2476 Mental Health for Latinos Act of 2023 H.R.4974, Local 988 Response Act H.R. 5866, Substance Use Disorder and Family Engagement (SAFE) in Recovery Act H.R. 6284/S. 3260 Improving Measurements for Loneliness and Isolation Act of 2023 H.R. 6475 Health Disparity Zones Act of 2023 H.R.6928 CONNECT Act of 2024 H.R. 7153/S. 3679 Dr. Lorna Breen Health Care Provider Protection Reauthorization Act H.R. 7301 Certified Community Behavioral Health Clinic Expansion Act of 2024 H.R. 8390 Mental Health and MAMA Act of 2024 H.R. 8503 Integrated Care for Dual Eligibles H.R. 9577 STOP Suicide Act H.R. 10073 Medicare Patient Access and Practice Stabilization Act of 2024 S.669/H.R. 8458 Increasing Mental Health Options Act of 2023 S. 923 Better Mental Health Care for Americans Act S. 1378/ H.R 5819 COMPLETE Care Act S.2350, National Strategy for Social Connection Act Reintroduction of The Behavioral Health Coverage Transparency Act Reintroduction of The Parity Enforcement Act of 2023 H.R. 5804, The Mental Health Infrastructure Improvement Act Reintroduction of The Comprehensive Addiction Resources Emergency Act Reintroduction of The Stop Online Suicide Assistance Forums Act S.2511, the ADAPT Act S. 2733, PEER Support Act H.R. 7808, EARLY Minds Act S.3364, Kids Providing Resources for Optimal Outcomes Against Fatalities Act of 2024 (KID Proof Act) S.3085, Preventing Adverse Childhood Experiences Act (PACE Act) S. 3393 SUPPORT for Patients and Communities Reauthorization Act S.3498 Promoting Effective and Empowering Recovery Services in Medicare Act of 2023 S. 3557 Public Health Impact of Opioid Drugs S. 3769, Alternative Pathways to Child Abuse Prevention Act S. 4312 United States Senate Commission on Mental Health Act of 2024 S. 4338 Pay PCPs Act of 2024 Reauthorization of the Older Americans Act Caregiving for older adults Title IV-B of the Social Security Act Mental Health Parity Final Rule Meeting with the Tri-Departments (DOL, HHS and Treasury) H.R 3312, S. 1602, Moms Matter Act S.4811, Prevention Services for Youth Act S.4812, Strengthening Supports for Youth Act H.R.9875, Child Safety and Well-Being Act Response to RFI regarding regulation of cannabis and hemp products Research regarding the safety and efficacy of psychedelic-assisted therapy Meeting with CMS on eligibility of postdoctoral training programs for Nursing/Allied Health Reimbursement   Flexibility to prescribe certain controlled medications via telehealth for the treatment of mental health and substance use disorders Support of the proposed rule on georouting solutions for the 988 Suicide & Crisis Lifeline (988 Lifeline) Medicare coverage policies regarding mental health and substance use disorder services Sickle Cell Disease Comprehensive Care Act (H.R. 7432 / S. 5097)

Client expense: $350,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Treasury, Dept of, White House Office

Legislation: H.R. 3074/S. 971 - Due Process Continuity of Care Act S. 1165/H.R.2400 - Reentry Act H.R. 4531 - SUPPORT Act Issues: Eliminating prior authorization requirements in Medicaid Medicare coverage for seniors with substance use disorder Medicaid reform in jails/prisons Methadone access Agencies Visited: US Senate US House of Representatives SAMHSA

Client expense: $300,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency. Joined coalition letter urging passage of the Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (H.R. 5819/S.1378), which would encourage the adoption of integrated delivery models that will make behavioral health services more accessible to patients. It would do this through a temporary increase in Medicare reimbursement rates for integrated care codes. ASAM joined over 60 organization signatories in a letter to the Centers for Medicare and Medicaid Services (CMS) regarding proposed guidance and templates for parity compliance in Medicaid and the Children's Health Insurance Program (CHIP). Joined coalition letter encouraging CMS to strengthen the Medicaid parity regulations by aligning them with parity regulations recently finalized for commercial plans. The letter also recommended that CMS amend the templates and guidance documents to more closely align with the federal parity statute and regulations. Joined coalition letter requesting that Congress pass legislation to both prevent the scheduled 2.83 percent Medicare physician payment cut and, critically, provide a positive payment update for 2025.

Client expense: $50,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency. Joined coalition letter urging passage of the Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (H.R. 5819/S.1378), which would encourage the adoption of integrated delivery models that will make behavioral health services more accessible to patients. It would do this through a temporary increase in Medicare reimbursement rates for integrated care codes. ASAM joined over 60 organization signatories in a letter to the Centers for Medicare and Medicaid Services (CMS) regarding proposed guidance and templates for parity compliance in Medicaid and the Children's Health Insurance Program (CHIP). Joined coalition letter encouraging CMS to strengthen the Medicaid parity regulations by aligning them with parity regulations recently finalized for commercial plans. The letter also recommended that CMS amend the templates and guidance documents to more closely align with the federal parity statute and regulations. Joined coalition letter requesting that Congress pass legislation to both prevent the scheduled 2.83 percent Medicare physician payment cut and, critically, provide a positive payment update for 2025.

Client expense: $50,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency. Joined coalition letter urging passage of the Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (H.R. 5819/S.1378), which would encourage the adoption of integrated delivery models that will make behavioral health services more accessible to patients. It would do this through a temporary increase in Medicare reimbursement rates for integrated care codes. ASAM joined over 60 organization signatories in a letter to the Centers for Medicare and Medicaid Services (CMS) regarding proposed guidance and templates for parity compliance in Medicaid and the Children's Health Insurance Program (CHIP). Joined coalition letter encouraging CMS to strengthen the Medicaid parity regulations by aligning them with parity regulations recently finalized for commercial plans. The letter also recommended that CMS amend the templates and guidance documents to more closely align with the federal parity statute and regulations. Joined coalition letter requesting that Congress pass legislation to both prevent the scheduled 2.83 percent Medicare physician payment cut and, critically, provide a positive payment update for 2025.

Client expense: $50,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency. Joined coalition letter urging passage of the Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (H.R. 5819/S.1378), which would encourage the adoption of integrated delivery models that will make behavioral health services more accessible to patients. It would do this through a temporary increase in Medicare reimbursement rates for integrated care codes. ASAM joined over 60 organization signatories in a letter to the Centers for Medicare and Medicaid Services (CMS) regarding proposed guidance and templates for parity compliance in Medicaid and the Children's Health Insurance Program (CHIP). Joined coalition letter encouraging CMS to strengthen the Medicaid parity regulations by aligning them with parity regulations recently finalized for commercial plans. The letter also recommended that CMS amend the templates and guidance documents to more closely align with the federal parity statute and regulations. Joined coalition letter requesting that Congress pass legislation to both prevent the scheduled 2.83 percent Medicare physician payment cut and, critically, provide a positive payment update for 2025.

Client expense: $50,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency. Joined coalition letter urging passage of the Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (H.R. 5819/S.1378), which would encourage the adoption of integrated delivery models that will make behavioral health services more accessible to patients. It would do this through a temporary increase in Medicare reimbursement rates for integrated care codes. ASAM joined over 60 organization signatories in a letter to the Centers for Medicare and Medicaid Services (CMS) regarding proposed guidance and templates for parity compliance in Medicaid and the Children's Health Insurance Program (CHIP). Joined coalition letter encouraging CMS to strengthen the Medicaid parity regulations by aligning them with parity regulations recently finalized for commercial plans. The letter also recommended that CMS amend the templates and guidance documents to more closely align with the federal parity statute and regulations. Joined coalition letter requesting that Congress pass legislation to both prevent the scheduled 2.83 percent Medicare physician payment cut and, critically, provide a positive payment update for 2025.

Client expense: $50,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency. Joined coalition letter urging passage of the Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (H.R. 5819/S.1378), which would encourage the adoption of integrated delivery models that will make behavioral health services more accessible to patients. It would do this through a temporary increase in Medicare reimbursement rates for integrated care codes. ASAM joined over 60 organization signatories in a letter to the Centers for Medicare and Medicaid Services (CMS) regarding proposed guidance and templates for parity compliance in Medicaid and the Children's Health Insurance Program (CHIP). Joined coalition letter encouraging CMS to strengthen the Medicaid parity regulations by aligning them with parity regulations recently finalized for commercial plans. The letter also recommended that CMS amend the templates and guidance documents to more closely align with the federal parity statute and regulations. Joined coalition letter requesting that Congress pass legislation to both prevent the scheduled 2.83 percent Medicare physician payment cut and, critically, provide a positive payment update for 2025.

Client expense: $50,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Medicare reimbursement for addiction counselors Medicare coverage for substance use disorder treatment services Consolidated Appropriations Act, 2023 implementation (S.923) Better Mental Health Care for Americans Act (H.R.2400/S.1165) Reentry Act (H.R. 1638/S. 838) Improving Access to Mental Health Act (S.3921/H.R. 4892) Medicaid Bump Act (H.R.6928) CONNECT Act of 2024 Gaps in substance use disorder services Issues surrounding peer support services (H.R. 6748/S. 3498) PEERS in Medicare Act Issues surrounding Medicare Part B (H.R. 9232/S. 4860) Residential Recovery for Seniors MHPAEA Application to Medicare (H.R.2400/S.1165) Reentry Act of 2023 (H.R.3074/S.971) Due Process Continuity of Care Act

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

No Bill No. - Congressional Primary Care Caucus No Bill No. - Black Maternal Health Momnibus Act No Bill No. - Medicare Physician Payment Reform No Bill No. - MACRA Implementation No Bill No. - CY2024 Medicare Physician Fee Schedule No Bill No. - CY 2024 Medicare Inpatient Prospective Payment System No Bill No. - Site Neutrality and Consolidation No Bill No. - CMS Prior Authorization Rules No Bill No. - Tobacco Users Quiet Act No Bill No. - G2211 Code (Physician Fee Schedule) No Bill No. - Reducing Medically Unnecessary Delays in Care Act No Bill No. - G2211 implementation/modifier 25 No Bill No. - HEALTH for Mom Act No Bill No. - Pay PCP Act No Bill No. - Seniors Timely Access to Care Act No Bill No. - CY25 Medicare Physician Fee Schedule No Bill No. - Physician Fee Stabilization Act (H.R. 952) Kids Access to Primary Care Act (H.R. 2400/S. 1165) The Reentry Act (H.R. 3074) Due Process Continuity of Care Act (H.R. 3766) Extending Access to Addiction Treatment Act (H.R. 4950/S. 2841) Improve Addiction Care Act (H.R. 4771) Children's Health Insurance Program Permanency Act (H.R. 4968) GOLD Card Act of 2023 (S. 2556) Improving Care for Youth Act (H.R. 5013) Value in Health Care Act (S. 2816) Medicaid for Every Child Act (H.R. 6545) Physician Fee Schedule Update and Improvements Act (H.R. 5434/S.3138) Stabilize Medicaid and CHIP Coverage Act (H.R. 5395) SURS Extension Act (H.R. 3487/S. 3805) No Fees for EFTs Act (S. 1316) Save Children's Coverage Act (H.R. 6997/S. 3010) Nutrition CARE Act (H.R. 6780/S. 2133) - Medically Tailored Home-Delivered Meals Demonstration Pilot Act (H.R. 8235) - Rural Physician Workforce Preservation Act (H.R. 7512) - Real-Time Benefit Tool Implementation Act (H.R. 1770/S. 2477) - Equitable Community Access to Pharmacist Act (S. 4349) - Electronic Prior Authorization for Prescription Drugs Act (H.R. 5434/S. 3138) - Stabilize Medicaid and CHIP Coverage Act (S. 5432) - Medicaid Primary Care Improvement Act (S. 5236) - Keeping Obstetrics Local Act

Client expense: $1,072,997 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Ensuring Excellence in Mental Health Act (CCBHC 2.0) (S. 2993/H.R. 8543), all provisions related to expansion grant funding for CCBHCs, childrens clinic grant funding, and CCBHC certification processes. Mental Health Access Improvement Act (S. 828/H.R. 432), all provisions related to allowing marriage and family therapists and mental health counselors to directly bill Medicare for their services. Medicaid Reentry Act (H.R. 2400/S. 1165), all provisions related to allowing Medicaid coverage for eligible incarcerated individuals to be re-established up to 30 days before their release from jail or prison. Due Process Continuity of Care Act (H.R. 3074/S. 971), all provisions related to the removal of the Medicaid coverage exclusion for inmates in custody pending disposition of charges. ADAPT Act (S.2511), all provisions related to allowing certain supervised psychology trainees to provide mental health services and bill Medicare, Medicaid and CHIP. PEERS in Medicare Act (H.R. 6748/S. 3498), all provisions related to creating a definition of peers in the Medicare program and making peer services reimbursable through Medicare in certain community-based settings. Residential Recovery for Seniors Act (S. 4860/H.R. 9232), all provisions related to establishing Medicare coverage for residential addiction treatment programs meeting nationally recognized standards. Language to expand NHSC allowable use of hours of service delivered outside clinic walls, all provisions related to expanding allowable use for hours of service.

Client expense: $112,806 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Medicaid Reentry Act (H.R. 2400/S. 1165) all provisions related to allowing Medicaid coverage for eligible incarcerated individuals to be re-established up to 30 days before their release from jail or prison. Residential Substance Use Disorder Treatment Act of 2023 (H.R. 238), all provisions related to reauthorize the residential substance use disorder treatment program. Bipartisan Safer Communities Act (S.2938), all provisions related to expanding access to mental health and behavioral health services and programs and funding of these programs. Due Process Continuity of Care Act (H.R. 3074/ S.971), all provisions relating to the continuation of Medicaid coverage for those who are detained pre-trial, and the creation of pathways to regain coverage after individuals leave carceral settings. Strengthening American Families Act (H.R. 5140) all provisions relating to the building and maintaining of Infant-Toddler-Court-Teams that work collaboratively to address the needs of babies and their families, preventing child abuse Safe Response Act (H.R.4089/ S2933) all provisions relating to the reauthorization of funding for first responder and community member trainings in the administration of Naloxone

Client expense: $112,806 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Kenneth P. Thompson Begin Again Act (S. 2596 / H.R. 4958); Keeping Violent Offenders Off our Streets Act (H.R. 8205); Inclusive Democracy Act (S. 3423, H.R. 6643); Clean Slate Act (H.R. 2930); Reentry Act (H.R.2400 / S.1165); Due Process Continuity of Care Act (H.R. 3074 / S.971); Fentanyl related substances and HALT Fentanyl Act (S. 1141 / H.R. 467); Weldon Angelos Presidential Pardon Expungements Act (H.R.10248); True Justice Act (H.R. 10496); Federal Public Defense Commission Act (S. 5526 / H.R. 10379); Rates for Interstate Inmate Calling Service; Marijuana Opportunity Reinvestment and Expungement (MORE) Act (H.R.5601); Cannabis Administration and Opportunity Act (CAOA) (S.4226); Right to Trial Act (H.R. 8856); SHIELD Act (S. 412; H.R. 3686); U.S. Sentencing Commission nominations; Fourth Amendment is Not for Sale Act (S. 2576 / H.R. 4639); National Defense Authorization Act

Client expense: $15,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), SENATE

Medicaid Reentry Act (H.R. 2400/S. 1165) all provisions related to allowing Medicaid coverage for eligible incarcerated individuals to be re-established up to 30 days before their release from jail or prison. Residential Substance Use Disorder Treatment Act of 2023 (H.R. 238), all provisions related to reauthorize the residential substance use disorder treatment program. Bipartisan Safer Communities Act (S.2938), all provisions related to expanding access to mental health and behavioral health services and programs and funding of these programs. Due Process Continuity of Care Act (H.R. 3074/ S.971), all provisions relating to the continuation of Medicaid coverage for those who are detained pre-trial, and the creation of pathways to regain coverage after individuals leave carceral settings. Strengthening American Families Act (H.R. 5140) all provisions relating to the building and maintaining of Infant-Toddler-Court-Teams that work collaboratively to address the needs of babies and their families, preventing child abuse Safe Response Act (H.R.4089/ S2933) all provisions relating to the reauthorization of funding for first responder and community member trainings in the administration of Naloxone

Client expense: $154,891 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Ensuring Excellence in Mental Health Act (CCBHC 2.0) (S. 2993/H.R. 8543), all provisions related to expansion grant funding for CCBHCs, childrens clinic grant funding, and CCBHC certification processes. Mental Health Access Improvement Act (S. 828/H.R. 432), all provisions related to allowing marriage and family therapists and mental health counselors to directly bill Medicare for their services. Medicaid Reentry Act (H.R. 2400/S. 1165), all provisions related to allowing Medicaid coverage for eligible incarcerated individuals to be re-established up to 30 days before their release from jail or prison. Due Process Continuity of Care Act (H.R. 3074/S. 971), all provisions related to the removal of the Medicaid coverage exclusion for inmates in custody pending disposition of charges. ADAPT Act (S.2511), all provisions related to allowing certain supervised psychology trainees to provide mental health services and bill Medicare, Medicaid and CHIP. PEERS in Medicare Act (H.R. 6748/S. 3498), all provisions related to creating a definition of peers in the Medicare program and making peer services reimbursable through Medicare in certain community-based settings. Residential Recovery for Seniors Act (S. 4860/H.R. 9232), all provisions related to establishing Medicare coverage for residential addiction treatment programs meeting nationally recognized standards. Language to expand NHSC allowable use of hours of service delivered outside clinic walls, all provisions related to expanding allowable use for hours of service.

Client expense: $154,891 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Protect the Medicaid program and oppose cuts to Medicaid, including statutory Medicaid DSH cuts FY 2025-FY 2027. Support legislation and administrative action to ease the Medicaid IMD exclusion and Medicaid inmate exclusion, including HR 1201, the Increasing Behavioral Health Treatment Act, HR 8575, the Michelle Alyssa Go Act, HR 2400/S 1165, the Reentry Act, HR 3074/S 971, the Due Process, Continuity of Care Act and the SUPPORT Act reauthorization bills, including HR 4531.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Protect the Medicaid system and oppose efforts to cut Medicaid, including support for legislation to repeal or delay statutory Medicaid DSH cuts for FY 2025-FY 2027, including HR 2665, the Supporting Safety Net Hospitals Act and related legislation. Support for reforming the Medicaid inmate exclusion, including HR 2400/S 1165, the Reentry Act, and HR 3074/ S 971, the Due Process, Continuity of Care Act, and related legislation.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation: H.R. 3074/S. 971 - Due Process Continuity of Care Act S. 1165/H.R.2400 - Reentry Act H.R. 1359/S.644 Modernizing Opioid Treatment Access Act H.R. 4531 - SUPPORT Act Issues: Eliminating prior authorization requirements in Medicaid Medicare coverage for seniors with substance use disorder Medicaid reform in jails/prisons Methadone access

Client expense: $440,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

General issues related to substance use prevention and treatment, including: Reentry Act (H.R. 2400 / S. 1165); Due Process and Continuity of Care Act (H.R. 3074/S. 971); and Modernizing Opioid Treatment Access Act (H.R. 1359 / S. 644), and the Support for Patients and Communities Reauthorization Act (H.R. 4531/S. 3393), and related provisions in FY24 consolidated appropriations bills (H.R. 2882 and H.R. 4366)

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Womens Health Protection Act Mental Health Workforce Shortages Meeting with various administrative agencies on expanding access to mental health care in rural areas Forthcoming House bill on capital investments in rural mental health Federal policies affecting access to contingency management services for substance use disorders H. R. 498 / S.1493, 9-8-8 Lifeline Cybersecurity Responsibility Act H.R. 501 Block, Report, And Suspend Suspicious Shipments Act H.R. 773/S. 3165, Homelessness and Behavioral Health Care Coordination Act of 2023 H.R. 1359/S. 644 Modernizing Opioid Treatment Access Act H.R. 1423 911 Community Crisis Responders Act of 2023 H.R. 1502 Comprehensive Opioid Recovery Centers Reauthorization Act of 2023 H.R. 2474 - The Strengthening Medicare for Patients and Providers Act H.R.2577/S.1137,DHS Suicide Prevention and Resiliency for Law Enforcement Act H.R. 3074/S. 971 The Due Process Continuity of Care Act HR 3305 Black Maternal Health Momnibus Act H.R. 3375 STOP Fentanyl Overdoses Act H.R. 3752 Parity Enforcement Act of 2023 H.R.4310/S.2233, Youth Poisoning Protection Act H.R. 4531 / S. 2433, SUPPORT for Patients and Communities Reauthorization Act of 2023 H.R. 4851, 9-8-8 Implementation Act of 2023 H.R. 4884 /S. 2476 Mental Health for Latinos Act of 2023 H.R.4974, Local 988 Response Act H.R. 5866, Substance Use Disorder and Family Engagement (SAFE) in Recovery Act H.R. 6284/S. 3260 Improving Measurements for Loneliness and Isolation Act of 2023 H.R. 6475 Health Disparity Zones Act of 2023 H.R.6928 CONNECT Act of 2024 H.R. 7301 Certified Community Behavioral Health Clinic Expansion Act of 2024 H.R. 8390 Mental Health and MAMA Act of 2024 H.R. 8503 Integrated Care for Dual Eligibles H.R. 9577 STOP Suicide Act S.669/H.R. 8458 Increasing Mental Health Options Act of 2023 S. 923 Better Mental Health Care for Americans Act S. 1378/ H.R 5819 COMPLETE Care Act S.2350, National Strategy for Social Connection Act Reintroduction of The Behavioral Health Coverage Transparency Act Reintroduction of The Parity Enforcement Act of 2023 H.R. 5804, The Mental Health Infrastructure Improvement Act Reintroduction of The Comprehensive Addiction Resources Emergency Act Reintroduction of The Stop Online Suicide Assistance Forums Act S.2511, the ADAPT Act S. 2688 / H.R. 5116, the Behavioral Health IT Coordination Act S. 2733, PEER Support Act H.R. 7808, EARLY Minds Act H.R. 6407 / S. 3297, Medical Nutrition Therapy Act S.3364, Kids Providing Resources for Optimal Outcomes Against Fatalities Act of 2024 (KID Proof Act) S.3085, Preventing Adverse Childhood Experiences Act (PACE Act) S. 3393 SUPPORT for Patients and Communities Reauthorization Act S.3498 Promoting Effective and Empowering Recovery Services in Medicare Act of 2023S. 3557 Public Health Impact of Opioid Drugs S. 3769, Alternative Pathways to Child Abuse Prevention Act S. 4312 United States Senate Commission on Mental Health Act of 2024 S. 4338 Pay PCPs Act of 2024 Dear Colleague letter to CMS re: coverage of digital therapeutics Reauthorization of the Older Americans Act Caregiving for older adults Title IV-B of the Social Security Act H.R. 3432/S. 3651, Telemental Health Care Access Act Mental Health Parity Final Rule Meeting with the Tri-Departments (DOL, HHS and Treasury) H.R 3312, S. 1602, Moms Matter Act S.4811, Prevention Services for Youth Act S.4812, Strengthening Supports for Youth Act H.R.9875, Child Safety and Well-Being Act Response to RFI re: 21st Century Cures 2.0 Response to RFI regarding regulation of cannabis and hemp products Research regarding the safety and efficacy of psychedelic-assisted therapy   Flexibility to prescribe certain controlled medications via telehealth for the treatment of mental health and substance use disorders Support of the proposed rule on georouting solutions for the 988 Suicide & Crisis Lifeline (988 Lifeline) Medicare coverage policies regarding mental health and substance use disorder services

Client expense: $400,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Labor, Dept of (DOL), Office of Faith-Based & Community Initiatives, Office of Management & Budget (OMB), SENATE, Treasury, Dept of

SUPPORT for Patients and Communities Reauthorization Act (HR 4531 / S 2433, S 3106, S 3393); HEAL Act (HR 4007 / S 2809); PAHPA Act (HR 4421 / S 2333); Reentry Act (HR 2400 / S 1165); Due Process Continuity of Care Act (HR 3074 / S 971); FY25 appropriations for Labor-HHS-Education, Military Construction & Veterans Affairs, and Commerce-Justice-Science; DEA rulemaking on telemedicine prescribing of controlled substances (RIN #1117-AB40); CMS Physician Fee Schedule CY25 Proposed Rule (RIN #0938-AV33)

Client expense: $230,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

H.R. 4531, SUPPORT for Patients and Communities Act H.R. 3074, Due Process Continuity of Care Act H.R. 2400, Reentry Act

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Public health legislation regarding County jail inmate access to Medicaid benefits (H.R. 2400, S. 1165, H.R. 3074, S. 971).

Client expense: Not reported · Firm income: $20,000

Monitor behavioral health legislation regarding County jail inmate access to Medicaid benefits. Support reforms to the Medicaid Inmate Exclusion Act (H.R. 2400/S. 1165/H.R. 3074/S. 971). Support FORWARD Act of 2023 (H.R. 6731).

Client expense: Not reported · Firm income: $20,000

No Bill No. - Congressional Primary Care Caucus No Bill No. - Black Maternal Health Momnibus Act No Bill No. - Medicare Physician Payment Reform No Bill No. - MACRA Implementation No Bill No. - CY2024 Medicare Physician Fee Schedule No Bill No. - CY 2024 Medicare Inpatient Prospective Payment System No Bill No. - Site Neutrality and Consolidation No Bill No. - CMS Prior Authorization Rules No Bill No. - Tobacco Users Quiet Act No Bill No. - G2211 Code (Physician Fee Schedule) No Bill No. - Reducing Medically Unnecessary Delays in Care Act No Bill No. - G2211 implementation/modifier 25 No Bill No. - HEALTH for Mom Act No Bill No. - Pay PCP Act No Bill No. - Seniors Timely Access to Care Act No Bill No. - CY25 Medicare Physician Fee Schedule No Bill No. - Physician Fee Stabilization Act (H.R. 952) Kids Access to Primary Care Act (H.R. 2400/S. 1165) The Reentry Act (H.R. 3074) Due Process Continuity of Care Act (H.R. 3766) Extending Access to Addiction Treatment Act (H.R. 4950/S. 2841) Improve Addiction Care Act (H.R. 4771) Children's Health Insurance Program Permanency Act (H.R. 4968) GOLD Card Act of 2023 (S. 2556) Improving Care for Youth Act (H.R. 5013) Value in Health Care Act (S. 2816) Medicaid for Every Child Act (H.R. 6545) Physician Fee Schedule Update and Improvements Act (H.R. 5434/S.3138) Stabilize Medicaid and CHIP Coverage Act (H.R. 5395) SURS Extension Act (H.R. 3487/S. 3805) No Fees for EFTs Act (S. 1316) Save Children's Coverage Act (H.R. 6997/S. 3010) Nutrition CARE Act (H.R. 6780/S. 2133) - Medically Tailored Home-Delivered Meals Demonstration Pilot Act (H.R. 8235) - Rural Physician Workforce Preservation Act (H.R. 7512) - Real-Time Benefit Tool Implementation Act (H.R. 1770/S. 2477) - Equitable Community Access to Pharmacist Act (S. 4349) - Electronic Prior Authorization for Prescription Drugs Act (H.R. 5434/S. 3138) - Stabilize Medicaid and CHIP Coverage Act

Client expense: $928,743 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for at least $10.5 billion for HRSA programs in the FY 2025 Labor, Health and Human Services, Education, and Related Agencies appropriations bill. Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Joined coalition letter recommending that CMS finalize a proposal to narrow Medicares in-custody definition to no longer include individuals on bail, parole, probation, and home detention. Joined coalition letter expressing support of proposed CMS actions to address Conditions of Participation for hospitals and critical access hospitals (CAHs) to improve maternal health outcomes. The letter requested that CMS expand the proposals to include substance use-related maternal health needs, recognizing that overdose is now a leading cause of maternal mortality. Submitted a comment letter to the Centers for Medicare and Medicaid Services (CMS) on proposed changes to enhance access to substance use disorder (SUD) and mental health treatment. In prepared comments, ASAM recommended revisions to proposed digital mental health treatment codes, adoption of payment/coverage of intensive outpatient (IOP) treatment in standalone settings, and welcomed a proposal to allow people on bail, parole, probation, home detention, or in halfway houses to qualify for Medicare coverage. Submitted comment letter to the Drug Enforcement Administration (DEA) on a proposed rule that if finalized, would move marijuana from Schedule I of the Controlled Substances Act (CSA) to Schedule III. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency.

Client expense: $60,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for at least $10.5 billion for HRSA programs in the FY 2025 Labor, Health and Human Services, Education, and Related Agencies appropriations bill. Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Joined coalition letter recommending that CMS finalize a proposal to narrow Medicares in-custody definition to no longer include individuals on bail, parole, probation, and home detention. Joined coalition letter expressing support of proposed CMS actions to address Conditions of Participation for hospitals and critical access hospitals (CAHs) to improve maternal health outcomes. The letter requested that CMS expand the proposals to include substance use-related maternal health needs, recognizing that overdose is now a leading cause of maternal mortality. Submitted a comment letter to the Centers for Medicare and Medicaid Services (CMS) on proposed changes to enhance access to substance use disorder (SUD) and mental health treatment. In prepared comments, ASAM recommended revisions to proposed digital mental health treatment codes, adoption of payment/coverage of intensive outpatient (IOP) treatment in standalone settings, and welcomed a proposal to allow people on bail, parole, probation, home detention, or in halfway houses to qualify for Medicare coverage. Submitted comment letter to the Drug Enforcement Administration (DEA) on a proposed rule that if finalized, would move marijuana from Schedule I of the Controlled Substances Act (CSA) to Schedule III. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency.

Client expense: $60,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for at least $10.5 billion for HRSA programs in the FY 2025 Labor, Health and Human Services, Education, and Related Agencies appropriations bill. Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Joined coalition letter recommending that CMS finalize a proposal to narrow Medicares in-custody definition to no longer include individuals on bail, parole, probation, and home detention. Joined coalition letter expressing support of proposed CMS actions to address Conditions of Participation for hospitals and critical access hospitals (CAHs) to improve maternal health outcomes. The letter requested that CMS expand the proposals to include substance use-related maternal health needs, recognizing that overdose is now a leading cause of maternal mortality. Submitted a comment letter to the Centers for Medicare and Medicaid Services (CMS) on proposed changes to enhance access to substance use disorder (SUD) and mental health treatment. In prepared comments, ASAM recommended revisions to proposed digital mental health treatment codes, adoption of payment/coverage of intensive outpatient (IOP) treatment in standalone settings, and welcomed a proposal to allow people on bail, parole, probation, home detention, or in halfway houses to qualify for Medicare coverage. Submitted comment letter to the Drug Enforcement Administration (DEA) on a proposed rule that if finalized, would move marijuana from Schedule I of the Controlled Substances Act (CSA) to Schedule III. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency.

Client expense: $60,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for at least $10.5 billion for HRSA programs in the FY 2025 Labor, Health and Human Services, Education, and Related Agencies appropriations bill. Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Joined coalition letter recommending that CMS finalize a proposal to narrow Medicares in-custody definition to no longer include individuals on bail, parole, probation, and home detention. Joined coalition letter expressing support of proposed CMS actions to address Conditions of Participation for hospitals and critical access hospitals (CAHs) to improve maternal health outcomes. The letter requested that CMS expand the proposals to include substance use-related maternal health needs, recognizing that overdose is now a leading cause of maternal mortality. Submitted a comment letter to the Centers for Medicare and Medicaid Services (CMS) on proposed changes to enhance access to substance use disorder (SUD) and mental health treatment. In prepared comments, ASAM recommended revisions to proposed digital mental health treatment codes, adoption of payment/coverage of intensive outpatient (IOP) treatment in standalone settings, and welcomed a proposal to allow people on bail, parole, probation, home detention, or in halfway houses to qualify for Medicare coverage. Submitted comment letter to the Drug Enforcement Administration (DEA) on a proposed rule that if finalized, would move marijuana from Schedule I of the Controlled Substances Act (CSA) to Schedule III. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency.

Client expense: $60,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for at least $10.5 billion for HRSA programs in the FY 2025 Labor, Health and Human Services, Education, and Related Agencies appropriations bill. Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Joined coalition letter recommending that CMS finalize a proposal to narrow Medicares in-custody definition to no longer include individuals on bail, parole, probation, and home detention. Joined coalition letter expressing support of proposed CMS actions to address Conditions of Participation for hospitals and critical access hospitals (CAHs) to improve maternal health outcomes. The letter requested that CMS expand the proposals to include substance use-related maternal health needs, recognizing that overdose is now a leading cause of maternal mortality. Submitted a comment letter to the Centers for Medicare and Medicaid Services (CMS) on proposed changes to enhance access to substance use disorder (SUD) and mental health treatment. In prepared comments, ASAM recommended revisions to proposed digital mental health treatment codes, adoption of payment/coverage of intensive outpatient (IOP) treatment in standalone settings, and welcomed a proposal to allow people on bail, parole, probation, home detention, or in halfway houses to qualify for Medicare coverage. Submitted comment letter to the Drug Enforcement Administration (DEA) on a proposed rule that if finalized, would move marijuana from Schedule I of the Controlled Substances Act (CSA) to Schedule III. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency.

Client expense: $60,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for at least $10.5 billion for HRSA programs in the FY 2025 Labor, Health and Human Services, Education, and Related Agencies appropriations bill. Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Joined coalition letter recommending that CMS finalize a proposal to narrow Medicares in-custody definition to no longer include individuals on bail, parole, probation, and home detention. Joined coalition letter expressing support of proposed CMS actions to address Conditions of Participation for hospitals and critical access hospitals (CAHs) to improve maternal health outcomes. The letter requested that CMS expand the proposals to include substance use-related maternal health needs, recognizing that overdose is now a leading cause of maternal mortality. Submitted a comment letter to the Centers for Medicare and Medicaid Services (CMS) on proposed changes to enhance access to substance use disorder (SUD) and mental health treatment. In prepared comments, ASAM recommended revisions to proposed digital mental health treatment codes, adoption of payment/coverage of intensive outpatient (IOP) treatment in standalone settings, and welcomed a proposal to allow people on bail, parole, probation, home detention, or in halfway houses to qualify for Medicare coverage. Submitted comment letter to the Drug Enforcement Administration (DEA) on a proposed rule that if finalized, would move marijuana from Schedule I of the Controlled Substances Act (CSA) to Schedule III. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency.

Client expense: $60,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

No Bill No. - Congressional Primary Care Caucus No Bill No. - Black Maternal Health Momnibus Act No Bill No. - Medicare Physician Payment Reform No Bill No. - MACRA Implementation No Bill No. - CY2024 Medicare Physician Fee Schedule No Bill No. - CY 2024 Medicare Inpatient Prospective Payment System No Bill No. - Site Neutrality and Consolidation No Bill No. - CMS Prior Authorization Rules No Bill No. - Tobacco Users Quiet Act No Bill No. - G2211 Code (Physician Fee Schedule) No Bill No. - Reducing Medically Unnecessary Delays in Care Act No Bill No. - G2211 implementation/modifier 25 No Bill No. - HEALTH for Mom Act No Bill No. - Pay PCP Act No Bill No. - Seniors Timely Access to Care Act (H.R. 952) Kids Access to Primary Care Act (H.R. 2400/S. 1165) The Reentry Act (H.R. 3074) Due Process Continuity of Care Act (H.R. 3766) Extending Access to Addiction Treatment Act (H.R. 4950/S. 2841) Improve Addiction Care Act (H.R. 4771) Children's Health Insurance Program Permanency Act (H.R. 4968) GOLD Card Act of 2023 (S. 2556) Improving Care for Youth Act (H.R. 5013) Value in Health Care Act (S. 2816) Medicaid for Every Child Act (H.R. 6545) Physician Fee Schedule Update and Improvements Act (H.R. 5434/S.3138) Stabilize Medicaid and CHIP Coverage Act (H.R. 5395) SURS Extension Act (H.R. 3487/S. 3805) No Fees for EFTs Act (S. 1316) Save Children's Coverage Act (H.R. 6997/S. 3010) Nutrition CARE Act (H.R. 6780/S. 2133) - Medically Tailored Home-Delivered Meals Demonstration Pilot Act (H.R. 8235) - Rural Physician Workforce Preservation Act (H.R. 7512) - Real-Time Benefit Tool Implementation Act

Client expense: $1,045,426 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

SUPPORT for Patients and Communities Reauthorization Act (HR 4531 / S 2433, S 3106, S 3393); HEAL Act (HR 4007 / S 2809); PAHPA Act (HR 4421 / S 2333); Reentry Act (HR 2400 / S 1165); Due Process Continuity of Care Act (HR 3074 / S 971); FY24 Further Consolidated Appropriations Act (HR 2882), FY25 appropriations for Labor-HHS-Education, Military Construction & Veterans Affairs, and Commerce-Justice-Science; DEA rulemaking on telemedicine prescribing of controlled substances (RIN #1117-AB40)

Client expense: $260,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

General issues related to substance use prevention and treatment, including: Reentry Act (H.R. 2400 / S. 1165); Due Process and Continuity of Care Act (H.R. 3074/S. 971); and Modernizing Opioid Treatment Access Act (H.R. 1359 / S. 644), and the Support for Patients and Communities Reauthorization Act (H.R. 4531/S. 3393), and related provisions in FY24 consolidated appropriations bills (H.R. 2882 and H.R. 4366)

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Monitor behavioral health legislation regarding County jail inmate access to Medicaid benefits. Support reforms to the Medicaid Inmate Exclusion Act (H.R. 2400/S. 1165/H.R. 3074/S. 971). Support FORWARD Act of 2023 (H.R. 6731).

Client expense: Not reported · Firm income: $20,000

Public health legislation regarding County jail inmate access to Medicaid benefits (H.R. 2400, S. 1165, H.R. 3074, S. 971).

Client expense: Not reported · Firm income: $20,000

Ensuring Excellence in Mental Health Act (CCBHC 2.0) (S. 2993), all provisions related to expansion grant funding for CCBHCs, childrens clinic grant funding, and CCBHC certification processes. Mental Health Access Improvement Act (S. 828/H.R. 432), all provisions related to allowing marriage and family therapists and mental health counselors to directly bill Medicare for their services. Medicaid Reentry Act (H.R. 2400/S. 1165), all provisions related to allowing Medicaid coverage for eligible incarcerated individuals to be re-established up to 30 days before their release from jail or prison. Due Process Continuity of Care Act (H.R. 3074/S. 971), all provisions related to the removal of the Medicaid coverage exclusion for inmates in custody pending disposition of charges. ADAPT Act (S.2511), all provisions related to allowing certain supervised psychology trainees to provide mental health services and bill Medicare, Medicaid and CHIP. PEERS in Medicare Act (H.R. 6748/S. 3498), all provisions related to creating a definition of peers in the Medicare program and making peer services reimbursable through Medicare in certain community-based settings. Ensuring Medicaid Continuity for Children in Foster Care Act of 2023 (H.R. 4056), all provisions relating to the allowance of Medicaid payment for services provided to children in foster care in residential treatment programs Language to expand NHSC allowable use of hours of service delivered outside clinic walls, all provisions related to expanding allowable use for hours of service.

Client expense: $149,440 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Medicaid Reentry Act (H.R. 2400/S. 1165) all provisions related to allowing Medicaid coverage for eligible incarcerated individuals to be re-established up to 30 days before their release from jail or prison. Residential Substance Use Disorder Treatment Act of 2023 (H.R. 238), all provisions related to reauthorize the residential substance use disorder treatment program. Bipartisan Safer Communities Act (S.2938), all provisions related to expanding access to mental health and behavioral health services and programs and funding of these programs. Due Process Continuity of Care Act (H.R. 3074/ S.971), all provisions relating to the continuation of Medicaid coverage for those who are detained pre-trial, and the creation of pathways to regain coverage after individuals leave carceral settings. Strengthening American Families Act (H.R. 5140) all provisions relating to the building and maintaining of Infant-Toddler-Court-Teams that work collaboratively to address the needs of babies and their families, preventing child abuse Safe Response Act (H.R.4089/ S2933) all provisions relating to the reauthorization of funding for first responder and community member trainings in the administration of Naloxone

Client expense: $149,440 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

No Bill No. - Congressional Primary Care Caucus No Bill No. - Black Maternal Health Momnibus Act No Bill No. - Medicare Physician Payment Reform No Bill No. - MACRA Implementation No Bill No. - CY2024 Medicare Physician Fee Schedule No Bill No. - CY 2024 Medicare Inpatient Prospective Payment System No Bill No. - Site Neutrality and Consolidation No Bill No. - CMS Prior Authorization Rules No Bill No. - Tobacco Users Quiet Act No Bill No. - G2211 Code (Physician Fee Schedule) No Bill No. - Reducing Medically Unnecessary Delays in Care Act No Bill No. - G2211 implementation/modifier 25 No Bill No. - HEALTH for Mom Act No Bill No. - Pay PCP Act No Bill No. - Seniors Timely Access to Care Act (H.R. 952) Kids Access to Primary Care Act (H.R. 2400/S. 1165) The Reentry Act (H.R. 3074) Due Process Continuity of Care Act (H.R. 3766) Extending Access to Addiction Treatment Act (H.R. 4950/S. 2841) Improve Addiction Care Act (H.R. 4771) Children's Health Insurance Program Permanency Act (H.R. 4968) GOLD Card Act of 2023 (S. 2556) Improving Care for Youth Act (H.R. 5013) Value in Health Care Act (S. 2816) Medicaid for Every Child Act (H.R. 6545) Physician Fee Schedule Update and Improvements Act (H.R. 5434/S.3138) Stabilize Medicaid and CHIP Coverage Act (H.R. 5395) SURS Extension Act (H.R. 3487/S. 3805) No Fees for EFTs Act (S. 1316) Save Children's Coverage Act (H.R. 6997/S. 3010) Nutrition CARE Act (H.R. 6780/S. 2133) - Medically Tailored Home-Delivered Meals Demonstration Pilot Act (H.R. 8235) - Rural Physician Workforce Preservation Act (H.R. 7512) - Real-Time Benefit Tool Implementation Act

Client expense: $1,045,426 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE